Actos, Takeda, and Now Omontys

Takeda, who is defending itself in the Actos litigation where type 2 diabetics have higher than anticipated occurrence of bladder cancer, may be on the verge of another blockbuster drug gone awry.  Recent reports in the Wall Street Journal indicate that the Takeda/Affymax anemia drug Omontys, which was approved by the FDA in April 2012, [...]